rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

New Enterprise Associates 14, L.P.

Director and 10% owner

Company insider

Files Form 4 as: Director and 10% owner, Synlogic; 10% owner, Enliven Therapeutics; 10% owner, Mersana Therapeutics; 10% owner, Mulesoft; 10% owner, Surface Oncology; 10% owner, Appian; 10% owner, Interleukin Genetics; 10% owner, Tracon Pharmaceuticals.

Every Form 4 they filed

In numbers

Trades disclosed
43
Buys
5
Sells
4
Bought
$18.0M
Sold
$55.2M
Companies
9
Companies where not an officer
9
First trade
6 Aug 2013
Last trade
27 Jul 2026
Last filed
14 Aug 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
SynlogicDirector, 10% owner · Biotechnology · last 27 Jul 20261 buy · 0 sells
ELVN Enliven Therapeutics10% owner · Biotechnology · last 25 Jan 20220 buys · 3 sells
Mersana Therapeutics10% owner · last 14 Sep 20200 buys · 0 sells
Mulesoft10% owner · last 1 May 20180 buys · 0 sells
Surface Oncology10% owner · last 23 Apr 20181 buy · 0 sells
APPN Appian10% owner · Software · last 13 Feb 20180 buys · 1 sell
Interleukin Genetics10% owner · last 29 Jul 20161 buy · 0 sells
Tracon Pharmaceuticals10% owner · last 4 Feb 20151 buy · 0 sells
Loxo Oncology10% owner · last 6 Aug 20141 buy · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
27 Jul 2026filed 14 Aug 2026Synlogicoption or derivative · BiotechnologySEC FORM 4 Code H—2,640,845filing
27 Jul 2026filed 14 Aug 2026Synlogicoption or derivative · BiotechnologySEC FORM 4 Code P—2,640,845filing
27 Jul 2026filed 14 Aug 2026Synlogicoption or derivative · BiotechnologySEC FORM 4 Code H—2,640,845filing
27 Jul 2026filed 14 Aug 2026Synlogicoption or derivative · BiotechnologySEC FORM 4 Code P—2,640,845filing
25 Jan 2022filed 25 Jan 2022ELVN Enliven TherapeuticsBiotechnologySEC FORM 4 Sold$151K102,952 at $1.47filing
24 Jan 2022filed 25 Jan 2022ELVN Enliven TherapeuticsBiotechnologySEC FORM 4 Sold$31K19,984 at $1.55filing
21 Jan 2022filed 25 Jan 2022ELVN Enliven TherapeuticsBiotechnologySEC FORM 4 Sold$19K11,622 at $1.67filing
14 Sep 2020filed 16 Sep 2020Mersana TherapeuticsSEC FORM 4 Code J—2,000,000 at $0.00filing
9 Apr 2020filed 13 Apr 2020Mersana TherapeuticsSEC FORM 4 Code J—4,000,000 at $0.00filing
1 May 2018filed 9 May 2018Mulesoftoption or derivativeSEC FORM 4 Code C—12,679,970filing
1 May 2018filed 9 May 2018MulesoftSEC FORM 4 Code C—12,679,970filing
1 May 2018filed 9 May 2018MulesoftSEC FORM 4 Code U—12,679,970filing
23 Apr 2018filed 23 Apr 2018Surface Oncologyoption or derivativeSEC FORM 4 Code C—6,995,000filing
23 Apr 2018filed 23 Apr 2018Surface OncologySEC FORM 4 Code C—3,179,544filing
23 Apr 2018filed 23 Apr 2018Surface OncologySEC FORM 4 Bought$2.0M133,333 at $15.00filing
13 Feb 2018filed 15 Feb 2018APPN AppianSoftwareSEC FORM 4 Code C—2,724,202filing
13 Feb 2018filed 15 Feb 2018APPN AppianSoftwareSEC FORM 4 Code J—2,724,202 at $0.00filing
13 Feb 2018filed 15 Feb 2018APPN Appianoption or derivative · SoftwareSEC FORM 4 Code C—2,724,202 at $0.00filing
20 Nov 2017filed 21 Nov 2017APPN AppianSoftwareSEC FORM 4 Code C—2,820,516filing
20 Nov 2017filed 21 Nov 2017APPN AppianSoftwareSEC FORM 4 Sold$55.0M2,820,516 at $19.49filing

Sectors

Health Care4
Technology1
Not placed4

Buys in green, sells in red, by the company’s sector.

Related people

Matthew W. CalkinsCEO and President · Also traded APPN in the last 90 days
J. Scott GarlandDirector · Also traded ELVN in the last 90 days
Benjamin HohlChief Financial Officer · Also traded ELVN in the last 90 days
Helen Louise CollinsChief Medical Officer · Also traded ELVN in the last 90 days
Mika K. DerynckDirector · Also traded ELVN in the last 90 days